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Abstract
Emerging evidence suggests that both adult cardiac cell and the cardiac stem/progenitor cell (CSPC) compartments are
involved in the patho-physiology of diabetic cardiomyopathy (DCM). We evaluated whether early administration of
Resveratrol, a natural antioxidant polyphenolic compound, in addition to improving cardiomyocyte function, exerts a
protective role on (i) the progenitor cell pool, and (ii) the myocardial environment and its impact on CSPCs, positively
interfering with the onset of DCM phenotype. Adult Wistar rats (n=128) with streptozotocin-induced type-1 diabetes were
either untreated (D group; n=54) or subjected to administration of trans-Resveratrol (i.p. injection: 2.5 mg/Kg/day; DR
group; n=64). Twenty-five rats constituted the control group (C). After 1, 3 or 8 weeks of hyperglycemia, we evaluated
cardiac hemodynamic performance, and cardiomyocyte contractile properties and intracellular calcium dynamics.
Myocardial remodeling and tissue inflammation were also assessed by morphometry, immunohistochemistry and
immunoblotting. Eventually, the impact of the diabetic ‘‘milieu’’ on CSPC turnover was analyzed in co-cultures of healthy
CSPCs and cardiomyocytes isolated from D and DR diabetic hearts. In untreated animals, cardiac function was maintained
during the first 3 weeks of hyperglycemia, although a definite ventricular remodeling was already present, mainly
characterized by a marked loss of CSPCs and adult cardiac cells. Relevant signs of ventricular dysfunction appeared after 8
weeks of diabetes, and included: 1) a significant reduction in 6dP/dt in comparison with C group, 2) a prolongation of
isovolumic contraction/relaxation times, 3) an impaired contraction of isolated cardiomyocytes associated with altered
intracellular calcium dynamics. Resveratrol administration reduced atrial CSPC loss, succeeded in preserving the functional
abilities of CSPCs and mature cardiac cells, improved cardiac environment by reducing inflammatory state and decreased
unfavorable ventricular remodeling of the diabetic heart, leading to a marked recovery of ventricular function. These
findings indicate that RSV can constitute an adjuvant therapeutic option in DCM prevention.
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Introduction
Diabetes mellitus is an independent risk factor for left
ventricular dysfunction and is associated with a specific cardio-
myopathy (diabetic cardiomyopathy: DCM). DCM develops
independently of common co-morbidities [1–2] and can be
considered a maladaptation of the heart mostly driven by the
metabolic derangements that accompany diabetes mellitus.
Hyperglycemia and dyslipidemia seem to be central in the
pathogenesis of DCM via a series of maladaptive stimuli among
which oxidative stress has a pivotal role [3]. Cellular oxidative
stress leads to nuclear and mitochondrial DNA damage, altered
gene expression, apoptotic cell death, interstitial inflammation,
myocardial fibrosis and collagen accumulation [1,4–6], favoring
the occurrence of DCM phenotype.
Recent studies reported that high glucose levels lead to
endothelial progenitor cell (EPC) senescence, and impaired
proliferation, adhesion, and migration capacities [7–8] resulting
in decreased neoangiogenesis. Emerging evidence also suggests
that the cardiac stem/progenitor cell (CSPC) compartment is
involved in the occurrence of diabetic cardiac dysfunction [9].
Hyperglycemia-induced CSPC damage may negatively affect
cardiac structure and function playing a specific and relevant role
in the pathophysiology of DCM that develops independently of
vascular disease.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39836It has been shown that several sub-populations of CSPCs
reside within the adult heart and possess the ability to
differentiate into all constituent cells of cardiac tissue including
cardiomyocytes, vascular smooth muscle, endothelial cells and
fibroblasts [10]. In early phases of diabetes, the activation of
CSPCs associated with proliferation of functionally competent
and properly integrated myocytes was shown to represent a
compensatory mechanism to counteract cell loss and to preserve
cardiac electromechanical performance [11]. However, later
phases of diabetes are characterized by progressive CSPC
damage and exhaustion associated with loss of the physiologic
cell turnover, leading to overt ventricular dysfunction [9]. Thus,
strategies aimed at preserving both parenchymal cells and the
pool of progenitor cells responsible for tissue homeostasis may
represent an innovative approach for DCM prevention and
treatment.
Reactive oxygen species (ROS) modulate progenitor cell
growth and survival: high levels of oxidative stress trigger
cellular damage pathways and are critically involved in CSPC
loss [12]. It follows that therapies able to reduce ROS and to
enhance ROS scavenging systems should have therapeutic
efficacy in preventing CSPC damage. Resveratrol (RSV: trans-
3,5,49-trihydroxystilbene), a polyphenolic compound and natu-
rally occurring phytoalexin present in red wine and vegetable
foods, might constitute an effective therapeutic adjuvant to
prevent the occurrence of DCM. Besides its antioxidant, anti-
apoptotic/anti-inflammatory effects, RSV was shown to exert
several other cardioprotective actions, in both ischemic and
diabetic rat heart [13–14]. In experimental models of diabetes,
it has been reported that RSV administration reduces reactive
oxygen species [15] and the incidence of cardiomyocyte death
[16–17], and improves cardiac function by enhancing the
expression of sarcoplasmic calcium ATPase (SERCA2a) in
cardiomyocytes, through the activation of deacetylase silent
information regulator 2/sirtuin 1 (SIRT1) [18–19]. Recent data
also indicate that RSV may exert beneficial effects on cultured
human circulating endothelial progenitor cells, at least in part
mediated by inhibited p38-phosphorylation and enhanced NO
levels [20]. Finally, in rat models of myocardial infarction
subjected to stem-cell regenerative therapy, pre-treatment with
RSV was shown to enhance stem cell survival and proliferation
[21].
Up to now RSV-induced improvement in the number and
function of adult CSPCs in the diabetic heart remains to be
explored. In the present study we addressed this issue in a rat
model of type-1 diabetes. Following an approach from intact
animal to tissue-cellular-molecular level, we tested the hypothesis
that early administration of RSV can prevent the onset and
development of DCM phenotype. We evaluated the potential
protective role of RSV at different times after the induction of
hyperglycemia on (i) the progenitor cell compartment, (ii) the
myocardial environment and its impact on CSPC survival and
functional properties, (iii) the changes in the relative expression
of the skeletal actin isoform usually associated with the
progression of myocardial damage [22]. The functional coun-
terpart of the above processes was also evaluated, in terms of
hemodynamics and cardiomyocyte contractile properties.
We found that early RSV administration succeeded in
preserving the numerical density and functional abilities of both
CSPCs and mature cardiac cells, improved cardiac environment
by reducing inflammatory state and decreased unfavorable
ventricular remodeling of the diabetic heart, leading to a marked
recovery of ventricular function.
Methods
The investigation was approved by the Veterinary Animal Care
and Use Committee of the University of Parma-Italy and
conforms to the National Ethical Guidelines of the Italian Ministry
of Health (Permit number: 41/2009-B) and the Guide for the Care
and Use of Laboratory Animals (National Institute of Health,
Bethesda, MD,USA, revised 1996). All surgery was performed
under ketamine chloride anesthesia, and all efforts were made to
minimize suffering.
Animals and Housing
The study population consisted of 143 male Wistar rats (Rattus
norvegicus) aged 12–14 wk, weighing 373.962.7 g. Animals were
kept in unisexual groups of four individuals from weaning (4 wk
after birth) until the onset of the experiments, in a temperature-
controlled room at 22–24uC, with the light on between 7.00 AM
and 7.00 PM. The bedding of the cages consisted of wood
shavings, and food and water were freely available. In 118 animals
(Group D), diabetes was induced by a single intra-peritoneal
injection of streptozotocin (STZ, 60 mg/kg) while the remaining
25 control rats (group C) were injected only with saline vehicle
(0.9% NaCl). Glucose blood levels and body weights were
measured in 2-hour-fasting animals, before STZ or vehicle
injection, two days after injection, and then weekly until sacrifice.
The blood glucose cut-off was fixed at 250 mg/dl, as measured
two days after STZ injection. About 8% of the STZ-injected
animals did not reach this threshold. These animals were excluded
from the study. In no animals a reversal of diabetes was observed.
D animals were either untreated (n=54) or subjected to chronic
administration of low doses of trans-Resveratrol (Sigma, Milan,
Italy), by intraperitoneal injection of 2.5 mg/Kg/day (DR groups,
n=64). This dose of RSV was selected on the basis of preliminary
results obtained in a pilot study, as described in the Supporting
information (Files: Text S1, Figure S1 and Table S1). The
treatment started immediately after the documented increase in
glucose blood levels (2 days after STZ injection). RSV was
dissolved in ethanol to prepare a stock solution (RSV concentra-
tion: 12.5 mg/mL) and stored in the dark at 4uC. For each animal,
just before i.p. injection, an appropriate aliquot was taken from the
stock solution and diluted in PBS to reach the desired concentra-
tion in a final volume of 200 mL. Functional measurements and
sacrifice were performed 1 week (D1, D1R groups), 3 weeks (D3,
D3R) or 8 weeks (D8, D8R) after induction of hyperglycemia.
Functional Measurements
Hemodynamic study. Invasive hemodynamic data were
recorded in 83 rats (12 D1, 17 D1R, 10 D3, 13 D3R, 8 D8, 11
D8R, and 12 C). Each rat was anaesthetized with ketamine
chloride 40 mg/kg i.p. (Imalgene, Merial, Milano, Italy), plus
medetomidine hydrochloride 0.15 mg/kg i.p. (Domitor, Pfizer
Italia S.r.l., Latina, Italy).
The right carotid artery was cannulated with a microtip
pressure transducer catheter (Millar SPC-320, Millar Instruments,
Houston, TX, USA) connected to a recording system (Power
Laboratory ML 845/4 channels, 2Biological Instruments, Be-
sozzo, Italy) and systolic and diastolic blood pressures were
determined. The catheter was then advanced into the left ventricle
to measure: ) LV systolic pressure (LVSP), 2) LV end-diastolic
pressure (LVEDP), 3) the peak rate of rise and decline of LV
pressure (6dP/dt), taken as indexes of myocardial mechanical
efficiency, 4) isovolumic contraction time (IVCT: duration of
isovolumic contraction), and 5) LV relaxation time (LVRT),
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package CHART B4.2).
Then, the hearts of D, DR and C rats were divided in two
subgroups and used for electrophoresis and immunoblot assay
(n=3 for each group) or morphometric and immunohistochemical
analyses (see below).
Myocyte isolation and measurement of cell
mechanics. The remaining 60 rats were used for cardiomyo-
cyte and CSPC isolation. From the hearts of 8 D1, 8 D1R, 8 D3, 9
D3R, 8 D8, 6 D8R, and 13 C rats, individual ventricular
myocytes were enzymatically isolated by collagenase perfusion in
accordance with a procedure previously described [24]. Briefly,
the rat heart was removed and rapidly perfused at 37uC by means
of an aortic cannula with the following sequence of solutions: 1) a
calcium-free solution for 5 min to remove the blood, 2) a low-
calcium solution (0.1 mM) plus 1 mg/ml type 2 collagenase
(Worthington Biochemical Corporation, Lakewood, NJ, USA),
and 0.1 mg/ml type XIV protease (Sigma, Milan, Italy) for about
20 min, and 3) an enzyme-free, low-calcium solution for 5 min.
Calcium-free solution contained the following (in mM): 126 NaCl,
22 dextrose, 5.0 MgCl2, 4.4 KCl, 20 taurine, 5 creatine, 5 Na
pyruvate, 1 NaH2PO4, and 24 HEPES (pH=7.4, adjusted with
NaOH), and the solution was gassed with 100% O2.
The LV was then minced and shaken for 10 min. The cells were
filtered through a nylon mesh and re-suspended in low-calcium
solutions for 30 min. Then, cells were used for measuring
sarcomere shortening and calcium transients. Smears were also
made, and LV cells were stained with toluidine-blue. For each
group, 500 cells were analyzed by optical microscopy to calculate
cell surface area. Mechanical properties of ventricular myocytes
were assessed by using the IonOptix fluorescence and contractility
systems (IonOptix, Milton, MA, USA).
LV myocytes were placed in a chamber mounted on the stage of
an inverted microscope (Nikon-Eclipse TE2000-U, Nikon Instru-
ments, Florence, Italy) and superfused (1 ml/min at 37uC) with a
Tyrode solution containing (in mM): 140 NaCl, 5.4 KCl,
1 MgCl2, 5 HEPES, 5.5 glucose, and 1 CaCl2 (pH 7.4, adjusted
with NaOH). Only rod-shaped myocytes with clear edges and
average sarcomere length $1.7 mm were selected for the analysis.
All the selected myocytes did not show spontaneous contractions.
The cells were field stimulated at a frequency of 1 Hz by
rectangular depolarizing pulses (2 ms in duration, and twice
diastolic threshold in intensity) by platinum electrodes placed on
opposite sides of the chamber, connected to a MyoPacer Field
Stimulator (IonOptix). The stimulated myocyte was displayed on a
computer monitor using an IonOptix MyoCam camera. Load-free
contraction of myocytes was measured with the IonOptix system,
which records the sarcomere pattern to calculate the changes in
the sarcomere spacing with a fast Fourier transform algorithm.
Then, frequency data were converted to length. A total of 638
isolated ventricular myocytes were analyzed (125 from C hearts,
85 from D1, 80 from D3, 83 from D8, 111 from D1R, 95 from
D3R and 59 from D8R) to assess cellular mechanical properties by
computing the following parameters: mean diastolic sarcomere
length, fraction of shortening (FS), and maximal rates of
shortening and re-lengthening (6dL/dt). Steady-state contraction
of myocytes was achieved before data recording.
In 30 cells of each group, Ca
2+ transients were measured
simultaneously with mechanical properties. Ca
2+ transients were
determined by epifluorescence after loading the myocytes with
10 mM fluo 3-AM (Invitrogen, Carlsbad, CA) for 30 min.
Excitation length was 480 nm, with emission collected at
535 nm using a 40X oil objective. Fluo 3 signals were expressed
as normalized fluorescence (f/f0: fold increase). The time course of
the fluorescence signal decay was described by a single exponential
equation, and the time constant (tau) was used as a measure of the
rate of intracellular calcium clearing.
CSPC Isolation and Cell Cultures
CSPC-isolation. CSPCs were isolated from the heart of
control rats. The isolation procedure was the same as for
cardiomyocytes, but ventricular fragments were maintained for a
longer time in a collagenase+albumine solution at 37uC to allow
mechanical tissue dissociation. The solution containing all cells
was washed several times, centrifuged at 300 rpm to remove
cardiomyocytes, and then submitted to Percoll (Sigma) gradient to
further enrich the fraction of small cells. The cell layer visualized
at the interface of the desired gradient was centrifuged at
1000 rpm and cells re-suspended in 10 ml of culture medium
containing Iscove Modified Dulbecco’s Medium (IMDM, Sigma)
supplemented with 1% Penicillin-Streptomycin (P/S, Sigma), 1%
Insulin-Transferrin-Sodium Selenite (I/T/S, Sigma), 10% Fetal
Bovine Serum (FBS, Sigma) and 10 ng/ml Basic-Fibroblast
Growth Factor (b-FGF, Sigma) and seeded in Petri dishes
(Corning, USA) placed at 37uC–5% CO2 for their amplification.
Daily, microscopic observation of cultures allowed the recognition
of two different adherent cell populations, one with mesenchymal-
like and one with monomorphic blast-like characteristics. This
latter population constitutes the so-called Cardiac Progenitor Cells
(CSPCs), which exhibit clonogenic growth, multipotency and self-
renewing ability, as extensively shown in rodent and human hearts
[10,25]. We used the term Cardiac Stem/Progenitor Cells
(CSPCs) because in our typical preparations a consistent fraction
of c-kit or Sca-1 positive cells in the heart expressed nuclear
transcription factors (GATA-4/MEF2C/GATA-6/ETS-1) indi-
cating cardiovascular lineage commitment [25]. These cells were
amplified for several passages and cryo-preserved in aliquots in a
medium composed by FBS supplemented with 1% Dimethyl-
sulphoxide (DMSO, Sigma).
Co-cultures: CSPCs-cardiomyocytes. In order to evaluate
whether and to which extent the functional properties of CSPCs
were affected by parenchymal cells of RSV-treated and untreated
hearts, control CSPCs (previously expanded from passage 1 to 4)
were seeded at a concentration of 35,000/cm
2 together with
ventricular cardiomyocytes (at a concentration of 18,000/cm
2)
isolated from untreated and RSV-treated D1, D3 and D8 hearts.
Growth (phospho-histone H3-positive CSPCs; polyclonal rabbit
anti-ph-H3, Upstate, Charlottesville, VA, USA) and survival
characteristics (TUNEL assay) of CSPCs were analyzed after 72
hours of co-culture.
Analysis of conditioned media. The conditioned medium
from each co-culture was harvested after 72 hours and evaluated
using RayBio Rat Cytokine Antibody Array II purchased from
RayBiotech (Norgross, GA, USA). This assay can simultaneously
detect the expression level of different cytokines with high
specificity (Table 1).
Briefly, after treating the membranes with a blocking buffer,
1 ml of conditioned medium was added and incubated at room
temperature for 2 hours. The membranes were washed, and 1 ml
of primary biotin-conjugated antibody was added and incubated
at room temperature for 2 hours. The membranes were then
incubated with 2 ml of horseradish peroxidase-conjugated strep-
tavidin at room temperature for 1 hour and subsequently
developed by using enhanced chemiluminescence-type solution
(Immobilon Western-Millipore) and exposed to Kodak X-Omat
AR film. The intensities of signals were quantified by densitometry
(software for image capturing and analysis: ImageQuant-Molec-
ular Dynamics). For each spot the net density was determined by
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control spots were used to normalize the results from the different
membranes.
Cardiac Anatomy and Morphometry
In 9 C, 9 D1, 14 D1R, 7 D3, 10 D3R, 5 D8 and 8 D8R rats, the
abdominal aorta was cannulated, the heart was arrested in diastole
with injection of CdCl2 solution (100 mM), and the myocardium
was retrogradely perfused with 10% buffered formalin solution.
The left ventricular chamber was filled with fixative at a pressure
equal to the in vivo measured systolic pressure. The heart was then
excised and placed in formalin solution (10%) for 24 hours.
Cardiac anatomy. The right ventricle (RV) and the left
ventricle (LV) inclusive of the septum were separately weighed and
the volume of the left ventricular myocardium was computed by
dividing LV myocardial weight by the specific weight of the tissue
(1.06 g/ml). LV chamber length was measured from the apex to
the aortic valve. A 1-mm-thick transverse slice was cut from the
mid-region of the LV and used to compute LV wall thickness and
chamber equatorial diameter (Image Pro-plus, Media Cybernetics,
Bethesda, MD, USA, version 7.0). The LV chamber volume was
calculated according to the Dodge equation which equalizes the
ventricular cavity to an ellipsoid [26]. The slice was then
embedded in paraffin and five-micrometer-thick sections were
cut and used for morphometric and immunohistochemical
analyses.
Morphometric analysis. Sections were stained with Mas-
son’s trichrome and analyzed by optical microscopy (magnification
250X) in order to evaluate in the ventricular myocardium: (i) the
volume fraction of myocytes, (ii) the volume fraction of interstitial
and perivascular fibrosis, and (iii) the numerical density and
average cross-sectional area of fibrotic foci. According to a
procedure previously described [27], for each section, these
analyses were performed in 60 adjacent fields from sub-endocar-
dium, mid-myocardium and sub-epicardium. The measurements
were obtained with the aid of a grid defining a tissue area of 0.160
mm
2 and containing 42 sampling points each of them covering an
area of 0.0038 mm
2.
Immunohistochemistry
Atrial and LV sections were analyzed to estimate (i) the
percentage of apoptotic cells (TUNEL assay), (ii) the numerical
density of cells expressing c-kit, the receptor for Stem Cell Factor
(rabbit polyclonal anti-c-kit antibody, Santacruz Biotechnology,
Santa Cruz, CA, USA), (iii) the relative expression of a-skeletal
actin (a-SKA) by using a specific monoclonal antibody against a-
SKA (clone 10D2, IgG2a). This antibody has been developed and
characterized in the Dept. of Pathology and Immunology,
University of Geneva, Switzerland [28]. In five animals of each
group, sections were used for immunohistochemistry with anti-a-
SKA antibody. Total heart sections were scanned using a fully
automated system (Mirax Scan, Zeiss, Oberkochen, Germany).
Images were subsequently analyzed and a-SKA positive cardio-
myocytes were quantified using the software Metamorph (Molec-
ular Devices, Sunnyvale, CA). Myocardial areas were considered
positive to the immunostaining when their pixel intensity values
overcame background values. Positive areas were then expressed
as percentage of the total heart section.
Electrophoresis and Immunoblot Assay
In 3 rats for each group, the hearts were excised, and the left
and right ventricles were weighed and immediately frozen at
280uC. Western blot assay was used to assess the expression levels
of high-mobility group box-1 protein (HMGB-1) as an index of
activation of pro-inflammatory signal cascades in ventricular
myocardial tissue.
The left ventricular tissue was mechanically fragmented in
liquid nitrogen, homogenized in Sample Buffer (62.5 mM Tris-
HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol,
50 mM DTT, 0.01% bromophenol blue) and boiled for 5 min.
For each animal, 50 mg of proteins were separated on 10%
polyacrylamide gels and electroblotted on nitrocellulose mem-
branes (Protran, Schleicher & Schuell, Dassel, Germany). Mem-
branes were blocked with 5% milk in TBS-T (Tris-Buffered Saline
Tween-20) and were incubated overnight at 4uC with the primary
antibody (anti-HMGB1 rabbit polyclonal antibody, Abcam,
Cambridge, UK). After washing the membranes, a second
incubation was performed for one hour at room temperature
with peroxidase conjugated affinity purified goat anti-rabbit
secondary antibody (Jackson Immunoresearch Laboratories, West
Grove, PA). Peroxidase activity was developed using the ECL
Western blotting system (Amersham, Rahn AG, Zu ¨rich, Switzer-
land), according to the instructions of the manufacturer. To
determine the expression levels of HMGB-1, blots were scanned
and the intensity of the band was quantified by means of the
ImageJ Program (NIH, Bethesda, MD, USA). Actin (anti-actin
rabbit polyclonal antibody, Sigma) was used as the loading control.
Statistical Analysis
Power analysis has been performed to evaluate the research
design and minimize Type II errors and sample size. Preliminary
hemodynamic data obtained in a pilot study have been used. The
ANOVA statistical test was used for computing the F value, the
significance level, the effect size and the non-centrality parameter
(PASW Statistics 18). Then, a-priori power analysis was used
(G*Power Version 3.1.2; Franz Faul, Kiel University, Germany)
by setting a=0.01 and b=0.05 (power 1-b=0.95) in accordance
with the suggestion of Cohen [29], to estimate total sample size
and the number of measurements required for each group.
Statistics of variables included mean6standard error (SE),
Multifactorial analysis of variance (1 way ANOVA followed by
Bonferroni’s test or Dunnett’s test when appropriate). Statistical
significance was set at p,0.05.
Table 1. Cytokine Antibody Arrays.
Activin A IL-4
Agrin IL-6
B7-2/CD86 IL-10
beta-NGF IL-13
CINC-1 Leptin
CINC-2alpha LIX
CINC-3 L-Selectin
CNTF MCP-1
Fas Ligand MIP-3alpha
Fractalkine MMP-8
GM-CSF PDGF-AA
ICAM-1 Prolactin R
IFN-gamma RAGE
IL-1alpha Thymus Chemokine-1
IL-1beta TIMP-1
IL-1 R6 TNF-alpha
IL-2 VEGF
doi:10.1371/journal.pone.0039836.t001
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Glucose Blood Levels and Body Weight
At the beginning of the experimental protocol, glucose blood
levels and body weight ranged respectively between 102–109 mg/
dl and 301–445 g, in the entire rat population. After STZ
injection, glucose blood levels were higher than those measured in
C group, at every time points of observation (Table 2). In diabetic
animals, body weight decreased by 15% during the first week of
hyperglycemia to remain essentially constant until 8 weeks
(Table 3). RSV treatment did not significantly affect both glucose
blood levels and body weight (Tables 2, 3).
Hemodynamics
Heart rate measured under anesthesia was similar in all
experimental groups (heart rate ranging from 195 and 220 bpm,
in the different groups). In comparison with C rats, all diabetic
groups exhibited significantly lower values of systolic LV pressure
(range: 103–112 mmHg vs. 100–150 mmHg measured in C) while
end-diastolic pressure was unchanged (range: 5–9 mmHg).
Marked signs of systolic and diastolic ventricular dysfunction
developed after 8 weeks of diabetes, including a significant
reduction in 6dP/dt (Figure 1 A–B), associated with a prolonga-
tion of both isovolumic contraction time (IVCT) and relaxation
time (LVRT) (Figure 1 C–D). In D8R group, RSV treatment
abolished the negative impact of diabetes on LV hemodynamics
and all parameters reached control values with the exception of
the rate of pressure decline during relaxation (-dP/dt) (Figure 1 B).
Cell Mechanics and Calcium Transients
Globally, 638 isolated ventricular myocytes were used for cell
mechanics (125 from C hearts, 85 from D1, 80 from D3, 83
from D8, 111 from D1R, 95 from D3R and 59 from D8R). In
30 cells of each experimental group, calcium transients were
simultaneously recorded. The average diastolic sarcomere length
was comparable in all groups (average sarcomere length equal
to 1.7160.002 mm).
In accordance with the in vivo recorded hemodynamic data,
the mechanical properties of ventricular myocytes from D1 and
D3 diabetic hearts were globally preserved (Figure 2 B–D),
except for the lower rate of intracellular calcium clearing (TAU)
in D3 (Figure 2 F). Conversely, a definite worsening of cell
mechanics occurred in D8 (Figure 2 A–D). In comparison with
C cells, D8 cardiomyocytes exhibited a reduced fraction of
shortening associated with a significant decrease in the maximal
rate of shortening (-dL/dt) and relengthening (+dL/dt) (p,0.01;
Figure 2 B–D). The impaired contractility in D8 cells was
accompanied by a significant decrease in calcium transient
amplitude (f/f0) (215%, p,0.01; Figure 2 E) and a prolonged
TAU (+50%, p,0.01; Figure 2 F). The progressive impairment
of cardiomyocyte contractile efficiency produced by diabetes was
partially improved by RSV treatment as shown by the recovery
of fraction of shortening and f/f0 (Figure 2 B, E).
Effects of Diabetes and RSV on Cardiac Anatomy and
Myocardial Tissue
Diabetes induced a marked loss of left ventricular mass in
D1, D3 and D8 untreated hearts (p,0.05; Figure 3 A), in the
absence of significant changes in individual cardiomyocyte size
(average cardiomyocyte surface area: approximately 1,400 mm
2,
data not shown). A significant dilation of LV chamber was
observed only after 8 weeks of diabetes (Figure 3 B) leading to a
marked reduction in mass-to-chamber volume ratio in D8 group
(Figure 3 C). These unfavorable anatomical changes produced
by diabetes were reversed by RSV administration (Figure 3 A–
C).
The total amount of collagen accumulation was negligible
and similar to control ventricles in RSV-treated and untreated
diabetic hearts during the first 3 weeks of hyperglycemia. In D8
group, although myocardial damage was still limited, the total
amount of fibrosis in the myocardium was significantly
increased in comparison with C (Figure 3 D). Perivascular
fibrosis was observed in association with small foci of reparative
fibrosis characterized by inflammatory cellular infiltrates
(Figure 3 E–F), more evident in the mid-myocardium. The
activation of pro-inflammatory signal cascades was confirmed by
the significant increase in HMGB-1 expression in D8 group, as
revealed by Western blotting assay (Figure 4 A). Cardiac
damage and inflammation signals were completely prevented by
RSV administration (Figure 3 D, 4 A).
Significantly lower values of a-SKA expression were also
detected in diabetic cardiomyocytes, after 3 and 8 weeks of
hyperglycemia (250% on average in both groups vs C; Figure 4
B–C). This reduction was counteracted by RSV-treatment in D3R
group (Figure 4 B–C) while the effect of RSV was less evident at
the later time point (D8R group).
Table 2. Glucose blood levels (mg/dl).
D1 D1R D3 D3R D8 D8R
Day 0 110610 10867 111661 1 5 611 101691 0 5 68
Day 2 371612* 404621* 399618* 38067* 370611* 433613*
Day 7 454616* 443613* 527630* 492631* 498643* 480622+
Day 14 554621* 527617* 510622* 505621*
Day 21 442636* 515618* 520625* 525623*
Day 28 528625* 568611*
Day 35 527621* 555618*
Day 42 526620* 546627*
Day 56 529618* 554620*
Values are mean 6 SE of glucose blood levels weekly measured in diabetic (D)
and RSV-treated diabetic rats (DR)
*p,0.01 significant differences from control animals.
doi:10.1371/journal.pone.0039836.t002
Table 3. Body weight (g).
D1 D1R D3 D3R D8 D8R
Day 0 38267 371653 6 3 610 374683 5 3 633 4 8 64
Day 7 34062 334611 341613 345610 335643 3 1 66
Day 14 334615 319610 342663 3 3 66
Day 21 335612 327683 4 0 673 3 6 67
Day 28 332610 31065
Day 35 332693 1 2 66
Day 42 331683 1 4 67
Day 56 346673 1 1 64
Values are mean 6 SE of body weight weekly measured in diabetic (D) and RSV-
treated diabetic rats (DR).
doi:10.1371/journal.pone.0039836.t003
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Endothelial Cell Apoptosis
To determine ongoing apoptotic cell death, tissue sections of
the LV myocardium were subjected to the TUNEL assay. In
comparison with control hearts, the percentage of apoptotic
cardiomyocytes increased with diabetes at all time points of
observation (Figure 5 A) while apoptosis in endothelial cells
increased from 3 to 8 weeks (Figure 5 B). Overall, RSV
treatment was able to reduce by 65% to 85% the incidence of
apoptotic cell death (Figure 5 A–B) although, after 8 weeks of
diabetes, a marked protective effect was maintained only on
endothelial cells (Figure 5 B).
Effects of Diabetes and RSV Treatment on CSPCs
Tissue analysis. To evaluate the effects of diabetes and RSV
treatment on the numerical density and tissue distribution of
CSPCs, sections of the atria and LV from all experimental groups
were immunostained for the detection of c-kit, the receptor of
Stem Cell Factor, representing the most preserved stem cell
antigen among different tissues of different species [30].
As expected, the quantitative analysis documented that in
control hearts the number of c-kit-positive CSPCs was 2.5 fold
higher in the atria with respect to the LV supporting the notion of
preferential sites of accumulation of cardiac primitive cells [31].
Diabetes significantly reduced the density of CSPCs in the atrial
appendages at all time points (Figure 5 C). Conversely, the
deleterious effect of diabetes on left ventricular CSPCs was
detected only after 8 weeks of hyperglycemia (Figure 5 D). RSV
administration significantly attenuated the early and late dramatic
depletion of CSPCs from the atrial sites of storage (Figure 5 C),
although was not able to counteract the late diabetes-induced loss
of progenitor cell compartments in the working left ventricle
(Figure 5 D).
In vitro analysis. It is well established that, especially at the
level of niches, stem cell function is tightly regulated by
environmental factors [32]. Thus, we determined in vitro whether
the negative impact of diabetes and the protective action of RSV
on CSPCs could be attributed to changes in myocardial
environment. Specifically, the effect of diabetic cardiomyocytes,
isolated from RSV-treated and untreated diabetic hearts, on the
magnitude of CSPCs apoptotic death (TUNEL) and proliferation
(Ph-H3) was analyzed.
CSPCs co-cultured with D1, D3 or D8 diabetic cardiomy-
ocytes exhibited a higher rate of death associated with a lower
proliferation capacity leading to an increased death-to-prolifer-
ation ratio, in comparison with CSPCs co-cultured with RSV-
treated cardiomyocytes, at all time points of observation
(Figure 6 A). However, no linear relationship with the duration
of diabetes was observed on this parameter. These in vitro
observations suggest that the diabetic ‘‘milieu’’ impairs CSPC
turnover which can be reversed by RSV. To investigate this
phenomenon, we determined the relative concentrations of
Figure 1. Hemodynamic measurements. Mean values 6 SE of: A) maximum rate of ventricular pressure rise (+dP/dt), B) maximum rate of
ventricular pressure reduction (-dP/dt), C) isovolumic contraction time (IVCT), and D) LV relaxation time (LVRT), measured in control rats (C) and
untreated or RSV-treated diabetic rats after 1 (D1, D1R), 3 (D3, D3R) and 8 (D8, D8R) weeks of hyperglycemia. *p,0.01: significant differences vs. C;
# p,0.05: significant differences between D8 and D8R.
doi:10.1371/journal.pone.0039836.g001
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condition (Table 1).
The presence of cardiomyocytes isolated from D1 and D3
untreated diabetic hearts mainly resulted in a higher concentration
of the monocyte chemotactic protein-1 (MCP-1) as compared with
the conditioned media collected from co-cultures containing RSV-
treated cardiomyocytes (D1R, D3R; Figure 6 B). These data
suggest that the inflammatory and pro-apoptotic bulk produced by
diabetes can be attenuated by chronic RSV administration.
Discussion
The most important finding of the present study is the
demonstration of positive effects of early RSV-treatment on
‘‘myocardial diabetic milieu’’ leading to a reduced inflammatory
state and attenuation of cell loss. The improved tissue environment
positively interferes with CSPC survival and functional properties,
resulting in a decreased ventricular remodeling produced by
diabetes. The functional counterpart of these effects consisted in
Figure 2. Cell mechanics and intracellular calcium transients. A) Representative examples of sarcomere shortening and corresponding
calcium transients (normalized tracings: fold increase) recorded from C and D8 ventricular myocytes. In bar graphs, the mean values 6 SE of: B)
sarcomere fraction of shortening, C) maximal rate of shortening (-dL/dt), D) maximal rate of relengthening (+dL/dt), E) calcium transient amplitude
expressed as peak fluorescence normalized to baseline fluorescence (f/f0), and F) time constant of the intracellular calcium decay (Tau), measured in
control myocytes (C) and untreated or RSV-treated diabetic cells (D and DR, respectively), after 1, 3 and 8 weeks of hyperglycemia. * p,0.01:
significant differences vs. C; # p,0.05: significant differences between D8 and D8R.
doi:10.1371/journal.pone.0039836.g002
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restoration of cardiomyocyte mechanical properties.
Although it is well accepted clinically that diabetes causes
myocardial dysfunction through accelerated atherosclerosis and
hypertension, there is evidence that DCM is a specific clinical
condition that occurs in diabetic patients in the absence of
coronary atherosclerosis and hypertension [2]. This suggests that
hyperglycemia and associated metabolic disturbances may ‘‘per-
se’’ negatively affect cardiac structure and function triggering
alterations in myocardial substrate which develop independently
of vascular disease. The STZ-rat model used in this study is
particularly relevant in examining the effects of hyperglycemia
alone on myocardial morpho-functional properties, in the
absence of hyperinsulinemia and atherosclerosis [2].
DCM consists of a series of structural and functional changes,
including chronic loss of myocytes and vascular cells leading to a
decrease in muscle mass, chamber dilation, altered extracellular
matrix and impaired systolic and diastolic ventricular function.
Accumulating evidence supports the concept that a ‘‘cardiac stem
cell compartment disease’’ plays an important role in the
pathophysiology of DCM [9]. Oxidative stress and inflammation
are enhanced with diabetes and can induce defects in both growth
and survival of CSPCs with a consequent imbalance between cell
death and cell replacement, favoring the onset of DCM and its
progression towards heart failure [33]. Thus, the preservation of
Figure 3. Cardiac anatomy and tissue morphometry. In A–C graphs the mean values 6 SE of the left ventricular (LV) geometrical properties
measured in the different experimental groups: A) LV mass, B) LV chamber volume, and C) LV mass to chamber volume ratio. In D) mean values 6 SE
of the volume fraction of fibrosis morphometrically determined in D8 and D8R groups. E–F: sections of LV mid-myocardium stained with Masson’s
trichrome showing in greenish blue the fibrotic tissue in a D8 rat heart. E: accumulation of collagen in perivascular space. F: focal damage
characterized by the presence of collagen and inflammatory cell infiltrate. Scale bars=100 mm. * p,0.05: significant differences vs. C; # p,0.05:
significant differences vs. the corresponding RSV-treated group.
doi:10.1371/journal.pone.0039836.g003
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impact of diabetes on the myocardium.
Despite several experimental studies suggesting that antioxi-
dants reduce diabetic cardiovascular complications, results from
clinical trials have been disappointing [4,34] probably because
traditional antioxidants have a scavenging action on already
formed ROS but limited effects on their intracellular production
[34]. Here, we tested the hypothesis that early administration of
RSV can be efficient in preventing DCM. In comparison with
conventional antioxidant compounds, RSV holds great promise in
the treatment of cardiovascular complications of diabetes due to its
well known effects on several target molecules resulting in reduced
inflammation and intracellular ROS production, decreased rate of
apoptotic cell death and increased cellular expression of survival
proteins. In addition, RSV was shown to enhance stem cell
survival and cardiac regeneration in ischemic heart [13,20,35–39].
RSV, as other natural phenolic compounds, at low doses
promotes antioxidant effects while at high doses can have a dose-
dependent pro-oxidant role followed by cell damage, p-Akt down-
regulation and apoptosis [40]. In the present study, the RSV dose
of 2.5 mg/Kg/day was selected on the basis of (i) experimental
and clinical data reported in the literature showing that the most
suitable doses of the compound leading to cardio-protection range
between 1 mg/Kg/day to 10 mg/Kg/day [17,41–43], (ii) avail-
able data on pharmacokinetics and metabolism of RSV [44–45],
and (iii) the results obtained in the pilot study reported in the
Supporting Information (Text S1), showing that 2.5 mg/Kg/day
and 5 mg/Kg/day led to comparable positive effects on cardiac
function, while the lower dose (1 mg/Kg/day) was less effective
(Figure S1).
Increased oxidative stress is the common element to all
pathways leading to cell dysfunction and apoptosis in diabetes
[2,33,46]. Hyperglycemia affects several other mechanisms leading
to the generation of advanced glycation end-products (AGEs) and
activation of diacylglycerol (DAG)-protein kinase C (PKC),
resulting in chronic inflammation [47–48]. This unfavorable tissue
environment, besides inducing myocyte/endothelial cell damage,
can impair mobilization, survival and proliferation of CSPCs. In
accordance with previous reports [9,11], we found a progressive
reduction in CSPC density both in atrial storage and ventricular
myocardial tissue of diabetic rats, partially reverted by RSV
administration. The critical role played by the adverse tissue
environment on CSPC survival and proliferation was also
supported by data obtained in the co-cultures of healthy CSPCs
and cardiomyocytes isolated from diabetic rats.
Co-cultureconditionedmediashowedahighconcentrationofthe
pro-inflammatorycytokinemonocytechemotacticprotein-1(MCP-
1). It has been recently shown [49] that hyperglycemia-induced
expressionofMCP-1andMCP-1-inducedprotein(MCPIP)leadsto
ROS production, endoplasmic reticulum stress, autophagy and
cardiomyocyte death, thus playing a critical role in the pathophys-
iological progression of diabetic cardiomyopathy [49]. Systemic
RSVtreatmentresultedinareducedactivationofpro-inflammatory
pathways,asindicatedbythelowerlevelsofMCP-1intheco-culture
supernatant. A reduced tissue inflammation was also confirmed by
the decreased inflammatory cell infiltration and lower expression of
HMGB-1 in the ventricular myocardium, after 8 weeks of diabetes.
HMGB-1, besides its well known nuclear function in eukaryotic
cells, possesses an extracellular role as pro-inflammatory cytokine
[50].ThefactthatpeakvaluesofMCP-1levelsweremeasuredinco-
culture media after 3 weeks of diabetes while HMGB-1 peaked at
tissue level after 8 weeks may just reflect a different temporal
implication of the two cytokines in the inflammatory process.
Oxidative stress results in enhanced MCP-1 expression triggering
monocytes/neutrophil infiltration (49), thus playing an important
role in the early phase of inflammation. The increased HMGB-1,
released in a passive way from necrotic cells or in an active way by
macrophages [51–52], acts as a late mediator of inflammation [53].
Ourfindingsareinaccordancewiththeseobservationsinthat:a)the
increased oxidative stress, the first negative impact of hyperglyce-
mia, leads to a marked apoptotic cell death [11], in the absence of
inflammatory infiltrate, and potentially triggers the increase in
MCP-1 expression; 2) infiltrating inflammatory cells and cardiomy-
Figure 4. HMGB-1 and alpha-SKA expression in left ventricular
myocardium. A–B: Expression levels of A) high mobility group box-1
protein (HMGB-1) and B) a-SKA, in left ventricular myocardial tissue.
Data are reported as mean 6 SE. * p,0.01: significant differences vs. C.
# p,0.05: significant differences vs. the corresponding RSV-treated
group. C: sections of D3 (upper panels) and D3R (lower panels) LV
myocardium stained with anti a-SKA. Black squares inscribe an area
shown at higher magnification in corresponding adjacent panels. Scale
bar=100 mm.
doi:10.1371/journal.pone.0039836.g004
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in the LV only at the late time point of diabetes (D8). Moreover, the
assessmentoftheexpressionofMCP1wascarriedoutinco-cultures
of cardiomyocytes with multipotent cells where only apoptotic cell
death occurred. The decrease in HMGB-1 expression in treated
animals after 8 weeks of diabetes (D8R) is allegedly due to the RSV-
induced reduction of both cardiac cell death and recruitment of
inflammatory cells.
Oxidative stress and tissue inflammation represent important
factors leading to lesions of small coronary arteries and appear-
ance of the perivascular/interstitial fibrosis occurring in diabetic
patients and in experimental models of diabetes [33]. The
antioxidant effect of RSV associated with the decrease in the
pro-inflammatory ‘‘milieu’’ may account for the preservation of
ventricular mass and the decreased fibrotic damage observed in
treated hearts, resulting in attenuation of cardiac remodeling and
improved myocardial function. In addition, it should be outlined
that, independently of the amount of loss in LV mass which was
comparable in all untreated groups (D1, D3 and D8), a significant
decrease in contractile efficiency was observed only in D8 animals,
both at the organ and cellular levels. This behavior can be
explained by considering that (a) significant alterations in the
extracellular matrix (myocardial fibrosis and inflammation),
affecting LV mechanical efficiency at the organ level, appeared
at the later time point of observation (D8) whereas they were
absent in D3 and D1; and 2) intracellular calcium handling was
significantly modified only in D8 isolated cardiomyocytes leading
to an impaired cellular contractile efficiency, while no significant
changes were observed at earlier time points (D1 and D3). Taken
together these findings suggest that, at these stages of diabetes, the
functional efficiency of individual cells and myocardial restructur-
ing play a more relevant role than LV mass itself in determining
cardiac performance.
Our data also indicate that diabetes affects the expression of a-
SKA in ventricular cardiomyocytes. During adult life, a-CA is the
main isoform present in myofibrils whereas a-SKA distribution
appears focal and represents about 5% of the total actin [22].
Previous studies showed that a higher a-SKA content is associated
with faster heart dynamics [54] and may constitute a compensa-
tion mechanism to maintain crossbridge turnover rate and achieve
a high degree of myocardial contractility in pressure-overload
cardiac hypertrophy [27]. Here, we found a significant reduction
in a-SKA levels after 3 and 8 weeks of hyperglycemia while RSV
treatment produced a recovery of a-SKA expression. Although
this effect was much more evident after 3 weeks of diabetes and
decreased with time, the early increment in a-SKA levels might
contribute to maintain a proper answer to increased workload with
a concurrent recovery of hemodynamic performance and cardio-
myocyte mechanical properties during contraction, as observed at
8 weeks of diabetes.
Figure 5. Effects of diabetes and RSV on myocardial cell apoptosis and CSPC number. Bar graphs illustrate the percentage of apoptotic
cardiomyocytes (A) and endothelial cells (B), and the numerical density of atrial (C) and ventricular (D) c-kit+ CSPCs. Data are expressed as mean
values 6 SE. * p,0.01: significant differences vs. C. # p,0.05: significant differences vs. the corresponding RSV-treated group.
doi:10.1371/journal.pone.0039836.g005
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preserves the numerical density and functional abilities of both
mature cardiac cells and atrial CSPC storage, improves cardiac
microenvironment and reduces unfavorable ventricular remodel-
ing. These positive effects of RSV led to an almost complete
recovery of global ventricular hemodynamics and to a partial
restoration of cardiomyocyte function at cellular level. Two
mechanisms underlying the cardioprotective effects of early RSV
treatment have been identified: (i) the reduced levels of pro-
inflammatory cytokines in the myocardial environment, as
demonstrated in vitro and at the tissue level, and (ii) the increase
in sarcomeric alpha-SKA expression which can contribute to
maintain contractile properties of ventricular myocytes. However,
further studies are required to achieve more mechanistic insights
on the molecular pathways involved in RSV-mediated prevention
of precocious CSPC aging, CSPC niche depletion, and cardio-
myocyte dysfunction, in the diabetic heart. It is also conceivable
that combining RSV administration with traditional drugs that
reduce metabolic derangements and glucose blood levels, and
strategies aimed at enhancing RSV bioavailability [44,55] can
increase and prolong the effects of the compound.
In conclusion, we demonstrated that early administration of
RSV can efficiently prevent the occurrence of DCM phenotype in
STZ-induced diabetes. This important finding deserves careful
consideration in future studies aimed at evaluating RSV as an
adjuvant therapeutic option in the treatment of DCM at later
stages of the disease.
Supporting Information
Figure S1 Hemodynamic measurements. Mean values 6
SE of: A) maximum rate of ventricular pressure rise (+dP/dt), B)
maximum rate of ventricular pressure reduction (-dP/dt), C)
isovolumic contraction time (IVCT), D) LV relaxation time
(LVRT), and E) total contraction-relaxation time, measured in
control rats (C) and untreated (D8) or treated diabetic rats with
different low doses of RSV: 1 mg/Kg/day (D8 R_1 mg), 2.5 mg/
Kg/day (D8 R_2.5 mg), and 5 mg/Kg/day (D8 R_5 mg).
*p,0.05: significant differences vs. C; 1-way ANOVA (post-hoc
analysis by Bonferroni test).
(TIF)
Table S1 Urine and plasma concentration of RSV
metabolites. Range and median values of RSV-metabolite
concentrations in urine and plasma samples of treated diabetic
rats. For each group, the number of animals used for the analysis is
indicated between brackets, in the first column. In each animal,
concentrations of RSV metabolites were assayed in duplicate
(urine) or quadruplicate (plasma). NQ = below the limit of
quantification.
(DOC)
Text S1 Detailed description of the preliminary exper-
iments performed to (i) verify dose-dependent effects of
long-term administration of RSV on functional param-
eters, and (ii) select the most suitable dose of the
compound.
(DOC)
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